Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ipsen names new chief executive officer

Ipsen names new chief executive officer

12th July 2016

Ipsen has announced the appointment of David Meek as its new chief executive officer, succeeding Marc de Garidel.

Mr Meek can offer more than 25 years of experience in the pharmaceutical industry, having held various global executive positions at companies such as Janssen, Novartis and Endocyte.

Most recently, he served as executive vice-president and president of the oncology division
of Baxalta, which was recently acquired by Shire. He helped to lead the formation of the business, rapidly creating an innovative oncology portfolio through strategic acquisitions and partnering deals.

The new chief executive will assume his post on July 18th, with Mr de Garidel set to assume the role of non-executive chairman, while continuing to serve on the Ipsen board of directors and providing advice to Mayroy, Ipsen's controlling holding company.

Mr de Garidel said: "I am confident that David will bring to our team new views, a new momentum and contribute to accelerating the sustainable growth of the group."

The launch of Cabometyx in advanced kidney cancer and Telotristat etiprate in neuroendocrine tumours is expected to bolster Ipsen's performance in the coming years, while Somatuline and Dysport are also showing strong prospects.ADNFCR-8000103-ID-801821645-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.